Roche's star MS medicine Ocrevus wins EU approval

ZURICH (Reuters) - The European Union approved Roche's multiple sclerosis medicine Ocrevus, one the Swiss company's key new drugs that likely neared $1 billion in revenue in its first nine months on the U.S. market.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news

Related Links:

Publication date: Available online 20 August 2018Source: Neurología (English Edition)Author(s): M. Mendibe Bilbao, S. Boyero Durán, J. Bárcena Llona, A. Rodriguez-AntigüedadAbstractBackgroundThe course of multiple sclerosis (MS) is influenced by sex, pregnancy and hormonal factors.AimsTo analyse the influence of the above factors in order to clarify the aetiopathogenic mechanisms involved in the disease.MethodsWe conducted a comprehensive review of scientific publications in the PubMed database using a keyword search for ‘multiple sclerosis’, ‘MS’, ‘EAE’, &lsquo...
Source: Neurologia - Category: Neurology Source Type: research
Oliver Findling, Heiko Rust, Özgür Yaldizli, Dionne P. H. Timmermans, Alja Scheltinga, John H. J. Allum
Source: Frontiers in Neurology - Category: Neurology Source Type: research
Condition:   Multiple Sclerosis Intervention:   Behavioral: Positive Psychology Sponsors:   Brigham and Women's Hospital;   Consortium of Multiple Sclerosis Centers;   Massachusetts General Hospital Recruiting
Source: - Category: Research Source Type: clinical trials
Gloria Castellazzi, Laetitia Debernard, Tracy R. Melzer, John C. Dalrymple-Alford, Egidio D'Angelo, David H. Miller, Claudia A. M. Gandini Wheeler-Kingshott, Deborah F. Mason
Source: Frontiers in Neurology - Category: Neurology Source Type: research
AbstractMultiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system with unknown etiology, which typically is manifested in early to middle adulthood. Recently, genome-wide association studies have identified susceptibility of immune-related genes to be involved in MS predisposition. The goal of the current study was to investigate the association of single nucleotide polymorphisms (SNP) with the immunologically related genes responsible for the disease, composed of CD58 (rs2300747 A>G), CD226 (rs763361 C>T), and HLA-G (rs1611715 A>C), with MS susceptibility. In this case ...
Source: Acta Neurologica Belgica - Category: Neurology Source Type: research
Conclusions These findings further confirm the use of circulating serum miRNAs as biomarkers to diagnose and monitor disease status in MS. Classification of evidence This study provides Class III evidence that levels of circulating miRNAs identify patients with MS.
Source: Neurology Neuroimmunology and Neuroinflammation - Category: Neurology Authors: Tags: Class III, Multiple sclerosis Article Source Type: research
Publication date: Available online 18 August 2018Source: Multiple Sclerosis and Related DisordersAuthor(s): Lorenzo Razzolini, Emilio Portaccio, Maria Laura Stromillo, Benedetta Goretti, Claudia Niccolai, Luisa Pastò, Isabella Righini, Elio Prestipino, Marco Battaglini, Antonio Giorgio, Nicola De Stefano, Maria Pia AmatoAbstractBackgroundDefinition of benign multiple sclerosis (BMS) remains controversial. Moreover, a sizeable proportion of classically defined BMS patients may be no longer benign (NLB) when re-assessed in the long-term. In a previous work we found that after a five –year follow-up, a clinical s...
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
Russell DeJong: "The most scholarly neurologist in the Academy". J Hist Neurosci. 2018 Jul-Sep;27(3):245-250 Authors: Reich SG Abstract Russell Nelson DeJong (1907-1990) became professor and chair of the Department of Neurology at the University of Michigan in 1950. A prolific author with more than 200 publications, DeJong wrote on virtually all areas of neurology. DeJong's classic monograph, The Neurologic Examination (1950), grew into an encyclopedic volume from lectures he gave to junior and senior medical students; DeJong saw it through four editions. He was one of the founders of the Ame...
Source: Journal of the History of the Neurosciences - Category: Neuroscience Tags: J Hist Neurosci Source Type: research
The objective of this study was to evaluate the effect of a rehabilitation program in changing the perception of fatigue in patients with multiple sclerosis. MATERIAL AND METHODS The study involved 65 respondents/patients with clinically confirmed multiple sclerosis (54 women, 11 men, average age 46.49 years). The evaluation of the effects of fatigue on the physical, psychological, and psychosocial aspects of life was assessed using the Modified Fatigue Impact Scale (MFIS). To test the effectiveness of the neurorehabilitation program, we enrolled 2 groups: the experimental group (EG, n=32, 29 women, 3 men, Expanded Disabil...
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research
King Exley Multiple sclerosis (MS) is a devastating and debilitating neurodegenerative disease of unknown cause. A consensus suggests the involvement of both genetic and environmental factors of which the latter may involve human exposure to aluminium. There are no data on the content and distribution of aluminium in human brain tissue in MS. The aluminium content of brain tissue from 14 donors with a diagnosis of MS was determined by transversely heated graphite furnace atomic absorption spectrometry. The location of aluminium in the brain tissue of two donors was investigated by aluminium-specific fluorescence mi...
Source: International Journal of Environmental Research and Public Health - Category: Environmental Health Authors: Tags: Article Source Type: research
More News: Health | Multiple Sclerosis | Switzerland Health